Research programme: IL1RAP-targeting antibody therapeutics - Cantargia

Drug Profile

Research programme: IL1RAP-targeting antibody therapeutics - Cantargia

Alternative Names: CANxx

Latest Information Update: 23 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Lund University
  • Developer Cantargia
  • Class Anti-inflammatories; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Interleukin 36 receptor antagonists; Interleukin-1 receptor accessory protein inhibitors; Membrane protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Chronic myeloid leukaemia; Solid tumours
  • Research Autoimmune disorders; Inflammation

Most Recent Events

  • 23 Aug 2017 Cantargia plans the phase I/IIa CANFOUR trial in Non-small cell lung cancer and Pancreatic cancer in Benelux and Scandinavia
  • 30 Jun 2017 Cantargia has patent protection for IL1RAP-targeting antibody for Acute lymphoblastic leukaemia in China
  • 26 Jun 2017 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the European, American and Italian cancer research organisations (EACR-2017, AACR-2017 and SIC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top